CSTL vs. EXEL

Last updated Apr 1, 2026

Compare and contrast key facts about Castle Biosciences, Inc. (CSTL) and Exelixis, Inc. (EXEL).

Performance

CSTL vs. EXEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Castle Biosciences, Inc. (CSTL) and Exelixis, Inc. (EXEL). The values are adjusted to include any dividend payments, if applicable.

CSTL vs. EXEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
CSTL Castle Biosciences, Inc.	-36.89%	45.97%	23.49%	-8.33%	-45.09%	-36.16%	95.37%	60.61%
EXEL Exelixis, Inc.	-2.14%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-14.59%

Fundamentals

Market Cap CSTL : $720.13M EXEL : $12.09B
EPS CSTL : -$0.82 EXEL : $2.76
PS Ratio CSTL : 2.09 EXEL : 5.24
PB Ratio CSTL : 1.53 EXEL : 5.59
Total Revenue (TTM) CSTL : $344.23M EXEL : $2.32B
Gross Profit (TTM) CSTL : $204.51M EXEL : $2.24B
EBITDA (TTM) CSTL : $8.22M EXEL : $934.65M

Returns By Period

In the year-to-date period, CSTL achieves a -36.89% return, which is significantly lower than EXEL's -2.14% return.

CSTL

• 1D: 4.25%
• 1M: -16.98%
• YTD: -36.89%
• 6M: 7.82%
• 1Y: 22.63%
• 3Y*: 2.62%
• 5Y*: -19.15%
• 10Y*: —

EXEL

• 1D: 2.24%
• 1M: -2.66%
• YTD: -2.14%
• 6M: 3.85%
• 1Y: 16.17%
• 3Y*: 30.25%
• 5Y*: 13.15%
• 10Y*: 26.62%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CSTL vs. EXEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CSTL

CSTL Risk / Return Rank: 56
CSTL Sharpe Ratio Rank: 55
CSTL Sortino Ratio Rank: 58
CSTL Omega Ratio Rank: 55
CSTL Calmar Ratio Rank: 54
CSTL Martin Ratio Rank: 55

EXEL

EXEL Risk / Return Rank: 56
EXEL Sharpe Ratio Rank: 56
EXEL Sortino Ratio Rank: 52
EXEL Omega Ratio Rank: 54
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CSTL vs. EXEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CSTL	EXEL	Difference
Sharpe ratio Return per unit of total volatility	0.38	0.37	+0.01
Sortino ratio Return per unit of downside risk	1.09	0.83	+0.26
Omega ratio Gain probability vs. loss probability	1.13	1.12	+0.01
Calmar ratio Return relative to maximum drawdown	0.51	0.67	-0.16
Martin ratio Return relative to average drawdown	1.30	1.55	-0.25
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CSTL vs. EXEL - Sharpe Ratio Comparison

The current CSTL Sharpe Ratio is 0.38, which is comparable to the EXEL Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of CSTL and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CSTL	EXEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.38	0.37	+0.01
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.26	0.36	-0.62
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.60	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.07	-0.04

Correlation

The correlation between CSTL and EXEL is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CSTL vs. EXEL - Dividend Comparison

Neither CSTL nor EXEL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CSTL vs. EXEL - Drawdown Comparison

The maximum CSTL drawdown since its inception was -88.02%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for CSTL and EXEL.

Drawdown Indicators

	CSTL	EXEL	Difference
Max Drawdown Largest peak-to-trough decline	-88.02%	-97.38%	+9.36%
Max Drawdown (1Y) Largest decline over 1 year	-45.33%	-25.34%	-19.99%
Max Drawdown (5Y) Largest decline over 5 years	-84.97%	-41.47%	-43.50%
Max Drawdown (10Y) Largest decline over 10 years	—	-57.20%	—
Current Drawdown Current decline from peak	-74.78%	-12.91%	-61.87%
Average Drawdown Average peak-to-trough decline	-54.08%	-71.55%	+17.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.78%	10.85%	+6.93%

Volatility

CSTL vs. EXEL - Volatility Comparison

Castle Biosciences, Inc. (CSTL) has a higher volatility of 9.82% compared to Exelixis, Inc. (EXEL) at 6.86%. This indicates that CSTL's price experiences larger fluctuations and is considered to be riskier than EXEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CSTL	EXEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.82%	6.86%	+2.96%
Volatility (6M) Calculated over the trailing 6-month period	36.73%	26.58%	+10.15%
Volatility (1Y) Calculated over the trailing 1-year period	59.76%	43.76%	+16.00%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	73.92%	36.84%	+37.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.42%	44.88%	+29.54%

Financials

CSTL vs. EXEL - Profitability Comparison

The chart below illustrates the profitability comparison between Castle Biosciences, Inc. and Exelixis, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CSTL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a gross profit of 0.00 and revenue of 87.01M. Therefore, the gross margin over that period was 0.0%.

EXEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a gross profit of 572.18M and revenue of 598.66M. Therefore, the gross margin over that period was 95.6%.

CSTL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported an operating income of -3.83M and revenue of 87.01M, resulting in an operating margin of -4.4%.

EXEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported an operating income of 235.22M and revenue of 598.66M, resulting in an operating margin of 39.3%.

CSTL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a net income of -2.33M and revenue of 87.01M, resulting in a net margin of -2.7%.

EXEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a net income of 244.53M and revenue of 598.66M, resulting in a net margin of 40.9%.